Introduction
Systematic review of randomized controlled trials of antenatal magnesium sulfate (MgSO 4 ) have reported that use of magnesium before preterm birth with the goal of neuroprotection, reduces the incidence of cerebral palsy and substantial gross motor dysfunction, although there was no reported significant effect on overall rate of neurological or development impairment, or developmental delay. 1 Although there was no evidence of a significant effect on perinatal mortality in this review including only trials that reported neurodevelopment, there is concern from a systematic review of trials enrolling women with preterm labor that use of MgSO 4 may increase perinatal mortality. 2 In addition, the mechanism of action of MgSO 4 in preventing cerebral palsy is unclear. In animal models, MgSO 4 may reduce the severity of hypoxic-ischemic damage, 3, 4 potentially by inhibiting calcium influx by blocking N-methyl-D-aspartic acid receptors. When neurons are damaged, they are unable to maintain glutamate homeostasis, leading to a cascade involving the influx of calcium and ultimately, neuronal cell death. 5 Magnesium may also have substantial cardiovascular effects in the mother and newborn producing vasodilation. 6, 7 It has been hypothesized this may increase uteroplacental blood flow. However, systematic review of trials of antenatal MgSO 4 for neuroprotection of the fetus found a significant increase in maternal hypotension and tachycardia. 6 The effect of antenatal MgSO 4 on the neonatal cardiovascular system is unclear with most trials not reporting these outcomes. The largest trial of antenatal MgSO 4 to date reported no significant difference in incidence of hypotension requiring inotrope. 8 Reduced Doppler indices of cerebral blood flow and perfusion pressure in infants in the first 24 h after birth have also been reported. 9 Trials of postnatal MgSO 4 for neuroprotection in term infants with hypoxic-ischemic encephalopathy have reported no increase in hypotension or incidence of persistent pulmonary hypertension. 10, 11 Small case series have reported an apparent benefit from use of postnatal MgSO 4 for persistent pulmonary hypertension of the newborn. [12] [13] [14] [15] In the first day after birth, when shunts frequently occur across the adapting heart, cardiac input (superior vena cava (SVC) flow) as a measure of systemic blood flow has been reproducibly reported to predict organ injury and neonatal outcome. [16] [17] [18] Low systemic blood flow in the first day has been associated with the development of late peri/intraventricular hemorrhage (PIVH), 16 subsequent developmental impairment 17, 18 and abnormal motor outcome 18 up to 3 years corrected age. Low systemic blood flow (SVC flow) was associated with decreasing gestation, increasing mean airway pressures (MAP), increased systemic vascular resistance and reduced myocardial contractility. 16, 19 However, there are no data reporting the effect of either antenatal or postnatal MgSO 4 on measures of systemic blood flow in very preterm infants.
The primary objective of this study was to determine the effect of antenatal administered MgSO 4 on echocardiographic measures of systemic blood flow in the first 24 h very preterm infants.
Methods
This study was a single center, 'nested' echocardiographic study within the Australasian Collaborative Trial of Magnesium Sulfate, a large multi-centred randomised placebo controlled trial that studied the effectiveness of antenatal treatment with MgSO 4 given to women at risk of preterm birth before 30 weeks gestation. 20 The echocardiographic study was conducted at Royal Prince Alfred Hospital Neonatal Intensive Care Unit, Sydney, Australia between May 1996 and August 2000. The study was approved by the Human Research Ethics Committee of the Central Sydney Area Health Service.
Participants
Women were eligible for enrollment if they had a singleton, twin, triplet or quadruplet pregnancy <30 weeks gestation and delivery was expected within the next 24 h. Women were excluded if they were in second stage of labor, if they had received MgSO 4 in this pregnancy or if there were contraindications to magnesium.
Randomization
Study randomization was by central computer generated random number sequence stratified by center, with variable block of 4, 6 or 8 with each study number placed on masked treatment packs. Eligible women, after providing informed consent, were given the next sequentially numbered treatment pack.
Interventions
The details of the intervention and monitoring have been reported previously. 20 Women were randomised to MgSO 4 4 g loading dose over 20 min (0.5 g ml À1 solution) followed by infusion 2 ml h À1 until birth or up to 24 h, or placebo (normal saline). Intervention was given for neuroprotection and not for tocolysis. Cardiovascular management of the infants varied across time with infants born before 1998 having clinical management by the attending physician with therapy largely directed at treating hypotension and blinded to echocardiographic information. During 1998 to 1999, a substantial proportion of the infants were enrolled in a separate echocardiographic directed study of indomethacin versus placebo for treatment of an early large patent ductus arteriosus (PDA), 21 and a concurrent blinded trial of normal saline and dobutamine versus normal saline and dopamine for infants with low SVC flow. 22 In both studies, physicians were blinded to the echocardiographic monitoring and interventions by use of a placebo or identical syringes for infusions. It should be noted that during this study, both groups of infants (exposed to antenatal MgSO 4 versus exposed to antenatal placebo) had equal chance of being in the echocardiographic treatment study (MgSO 4 exposed: 17/48 (35%); placebo exposed: 10/29 (34%)) and were treated with normal saline and inotrope only if they developed low SVC flow. The trial of indomethacin was a crossover trial so all infants with a large PDA received treatment with indomethacin.
Monitoring
Infants born <30 weeks gestation at Royal Prince Alfred Hospital underwent echocardiographic and head ultrasound monitoring at 3 to 5 h, 10 to 12 h and 24 h of age. The timing has been designed to encompass the period when low SVC flow has previously been reported. 16 An Acuson (Mountain View, CA, USA) 128/XP10 ultrasound scanner was used with a 7 MHz vector array transducer incorporating color flow and pulsed wave Doppler. The echocardiograms were performed by three different observers (DO, MK and NE). Structural normality of the heart was determined on the first echocardiogram. The haemodynamic parameters measured on echocardiogram were SVC flow, right ventricular output (RVO), diameter of the PDA and direction of flow of the ductal shunt (% right to left: defined as proportion (%) time pulse Doppler flow through the DA flowing left to right). The techniques for measuring SVC flow 23 and RVO and color Doppler diameter of PDA shunt 24 have been described previously. Upper body vascular resistance (UBVR) was calculated from concurrent mean blood pressure (BP) and SVC flow measurements: UBVR (mm Hg ml À1 kg À1 min À1 ) ¼ mean BP (mm Hg)CSVC flow (ml kg À1 min À1 ). Low SVC flow (<41 ml kg À1 min À1 ) 16 and low RVO (<120 ml kg À1 min À1 ) 24 were defined by previous data associating these levels of flow with adverse clinical outcome.
Clinical variables
A prospective data set was created to record maternal obstetric conditions (pre-eclampsia, abruption and preterm labor), treatment (antihypertensives, corticosteroidsFcomplete defined as >24 h before deliveryFand tocolysis) and delivery mode. Infant variables included gestation, birth weight, small for gestational age (<10th percentile), gender, mechanical ventilation, surfactant and use of indomethacin. At each echocardiogram, FiO 2 , MAP, heart rate (HR) and invasive BP if available were recorded. Neonatal outcomes included PIVH, pulmonary hemorrhage, pneumothorax, necrotizing enterocolitis (XBell stage 2) and cystic periventricular leucomalacia. Cerebral ultrasound was performed using a 7 MHz transducer and evidence of PIVH was looked for and classified according to Papile grading. Routine cranial ultrasound was also performed on day 7 and day 28. PIVH was defined as 'early' if it was documented on the initial cranial ultrasound at 3 to 5 h, and 'late' if noted for the first time on subsequent scans. Cystic periventricular leucomalacia was diagnosed on the day 28 ultrasound. 16 
Statistical analysis
All data analyses were performed according to intention to treat. Categorical data were analyzed using the w 2 test or Fisher's exact test. For continuous data, the mean±s.d. are presented with differences between treatment groups analyzed using the Student's t-test. Continuous data met assumptions for normality. Statistical significance was set at a P<0.05.
Results
In all, 114 women delivering 132 infants were enrolled in the Australasian Collaborative Trial of Magnesium Sulphate at Royal Prince Alfred Hospital. Of these, 67 infants were randomized to MgSO 4 and 65 to placebo. Echocardiography was performed on 87 infants (MgSO 4 48 and placebo 39). Reasons for losses are documented in Figure 1 . In the MgSO 4 group, all 48 infants had echocardiography performed at 3 to 5 and 10 to 12 h and 32 infants had an echo at 24 h.
In the placebo group, 39 infants had echocardiography at 3 to 5 h, 36 infants at 10 to 12 h and 23 at 24 h Infants who did not undergo echocardiographic monitoring were of significantly higher gestation (mean 28.1 versus 27.0 weeks) and similar birth weight (1058 versus 1027 g). There were no significant differences in rates of maternal hypertension, preterm labor, male gender and neonatal ventilation.
Pregnancy outcomes
Comparing infants who received MgSO 4 and placebo, there were no significant differences in pregnancy outcome and treatment including rates of pre-eclampsia, use of antihypertensives, abruption, preterm labor, complete antenatal corticosteroids, use of tocolysis, vaginal delivery and cesarean without labor (Table 1) . Infants born to mothers receiving MgSO 4 were of similar gestation (27.0 versus 27.0 weeks) and birth weight (1024 versus 1031 g) to infants of mothers receiving placebo. The rates of small for gestational age and male gender were similar. The majority of infants in both groups were mechanically ventilated (Table 2) , similar proportions received exogenous surfactant and had similar mean airway pressure and FiO 2 at initial echo (Table 2) .
Cardiovascular interventions
Infants of mothers receiving MgSO4 were significantly more likely to be given volume expansion (42% versus 21%, P ¼ 0.03). (Table 2 ). There was no significant difference in use of dobutamine (35% versus 21%), dopamine (17% versus 8%) or any inotrope (40% versus 26%). During this study the clinical practice included treating infants with hypotension (<10th percentile) and infants with low systemic blood flow (SVC flow <41 ml kg À1 min
À1
). Treatment of PDA was not significantly different between groups (38% versus 28%). Infants with a large echocardiographically detected PDA (>1.5 mm) received treatment.
Cardiovascular effects
In the first 24 h, there was no significant difference in the mean lowest SVC flow (53.8 versus 57.4 ml kg À1 min À1 ), incidence of low SVC flow (31% versus 26%), lowest RVO (165.2 versus 189.0 ml kg À1 min
À1
), RVO <120 ml kg À1 min À1 (25% versus 23%) and hypotension (40% versus 31%; Table 2 ).
At 3 to 5 h, there was no significant difference between MgSO 4 and placebo groups for mean, systolic or diastolic BP, incidence of hypotension (41% versus 22%, P ¼ 0.1) or UBVR ( 
Clinical outcome
There was no significant difference between MgSO 4 and placebo groups for any neonatal clinical outcome including incidence of pneumothorax, pulmonary hemorrhage (17% versus 5%), PIVH (29% versus 18%), cystic periventricular leucomalacia or mortality (19% versus 13%). No infant was diagnosed with necrotizing enterocolitis.
Discussion
This is the only study to document the effects of antenatal MgSO 4 for neuroprotection on systemic blood flow in very preterm infants. The findings are that infants exposed to antenatal MgSO 4 in general have similar cardiovascular outcomes compared to control infants with no significant difference in mean lowest SVC flow or RVO in the first 24 h, or incidence of low SVC flow or RVO. However, there is a concern that infants exposed to MgSO 4 received volume expansion significantly more frequently than control infants, and that at 10 to 12 h they had higher HR and a significantly higher incidence of low SVC flow. Although other cardiovascular and clinical outcomes were not significantly different, this study may not have had adequate power to detect important differences between groups. The possible explanations for the increased use of volume expansion include increased clinician concern regarding hypotension or an increase in the incidence of low systemic blood flow detected echocardiographically during the study, but not necessarily coinciding with the timing of the study measurements. It is unlikely volume expansion was used for other purposes. These concerns are consistent with the observational data from a previous study that maternal MgSO 4 was associated with decreased perfusion pressure and blood flow in the anterior cerebral artery and internal carotid artery during the first day of life. 9 They also reported systolic BP and pulse pressure were also lower during the whole study period in the MgSO 4 exposed infants compared with controls. Although our study did not show a significant difference in BP, there was a trend to lower mean, systolic and diastolic BP at 3 to 5 h in the MgSO 4 exposed infants. Reports on the association of antenatal MgSO 4 and early neonatal hypotension are inconsistent. To date, systematic review of the use of antenatal MgSO 4 has found that for trials reporting neurodevelopmental outcomes, there is a significant reduction in cerebral palsy and substantial gross motor impairment which are probably measuring the same injury. 26 Reported data to date do not allow confident conclusions regarding the mechanism by which MgSO 4 prevents cerebral palsy. MgSO 4 has been associated with a variety of maternal and neonatal cardiovascular effects, some of which have the potential for harm including maternal hypotension and tachycardia, 6 and the reports of reduced neonatal cerebral blood flow and perfusion pressure, 9 and this study that found an increase in use of volume expansion in infants exposed to MgSO 4 . It may be that other proposed mechanisms are more important including its effects in excitotoxicity, regulation of vascular tone in the fetus and/or uterus, stabilization of membranes and reduction of free radicals, regulation of the glycolytic cycle, and effects on platelet aggregation and adhesion. 7 A recent editorial addressing the role of MgSO 4 for neuroprotection of the fetus highlights the need to carefully consider Bradford Hill's criteria when considering cause and effect. 27 Data supporting the use of MgSO 4 do not provide a totally convincing case regarding strength of association, dose response, consistency of association and biological plausibility.
This study provides randomised controlled trial data for the haemodynamic effects of antenatal MgSO 4 for neuroprotection of the fetus. Despite the losses after randomization, the infants were well balanced at baseline and echocardiographic evaluations were performed blinded to treatment and by observers skilled in echocardiographic evaluation of the preterm infant. The measurements of systemic blood flow including SVC flow and RVO have been reported to have reasonable reliability, 23, 24 and SVC flow has been shown to be predictive of outcome including neonatal mortality, late PIVH and necrotizing enterocolitis, 16 and subsequent developmental impairment 17, 18 and abnormal motor outcome 18 up to 3 years corrected age. The study lacks power to detect important differences in cardiovascular outcomes. Despite this, there was relatively little difference in lowest SVC flow in the first 24 h and the incidence of low SVC flow. This may have been masked by the increased use of volume expansion found in the MgSO 4 group. Volume expansion has previously been reported to increase SVC flow by a mean of 43% 20 min after infusion of 10 ml kg À1 normal saline. 22 In conclusion, antenatal MgSO 4 used for neuroprotection of the fetus at risk of delivery before 29 weeks gestation produced no consistent cardiovascular effects in the infant in the first 24 h. There was a significant increase in use of volume expansion in the MgSO 4 group and infants in the MgSO 4 group had significantly higher HR and a significantly higher incidence of low SVC flow at 10 to 12 h but not other times. There is no evidence from this study to suggest that the mechanism by which antenatal MgSO 4 prevents cerebral palsy is through its cardiovascular effect in the newborn in the first 24 h.
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